Drug Type Small molecule drug |
Synonyms Tavapadon (USAN) + [3] |
Mechanism D1 receptor agonists(Dopamine D1 receptor agonists), D5 receptor agonists(Dopamine D5 receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC19H16F3N3O3 |
InChIKeyAKQXQLUNFKDZBN-UHFFFAOYSA-N |
CAS Registry1643489-24-0 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Young onset Parkinson disease | Phase 3 | FR | 13 Dec 2019 | |
Young onset Parkinson disease | Phase 3 | PL | 13 Dec 2019 | |
Young onset Parkinson disease | Phase 3 | US | 13 Dec 2019 | |
Young onset Parkinson disease | Phase 3 | DE | 13 Dec 2019 | |
Young onset Parkinson disease | Phase 3 | CZ | 13 Dec 2019 | |
Young onset Parkinson disease | Phase 3 | UA | 13 Dec 2019 | |
Young onset Parkinson disease | Phase 3 | IL | 13 Dec 2019 | |
Young onset Parkinson disease | Phase 3 | BG | 13 Dec 2019 | |
Young onset Parkinson disease | Phase 3 | CA | 13 Dec 2019 | |
Young onset Parkinson disease | Phase 3 | ES | 13 Dec 2019 |
Phase 3 | - | (kdajmeovcv) = Patients treated with tavapadon adjunctive to LD experienced a clinically meaningful increase of 1.1 hours in total “on” time without troublesome dyskinesia compared to those treated with LD and placebo. dmnlmtgxwy (dtvxuwgusy ) Met View more | Positive | 18 Apr 2024 | |||
Phase 2 | 57 | (ejhnezpfkh) = ybbgmvquqr ruvjjfqdmb (eggyomurid, 1.54) | Positive | 06 Mar 2020 | |||
Placebo | (ejhnezpfkh) = njudfxciww ruvjjfqdmb (eggyomurid, 1.65) | ||||||
Phase 2 | 5 | acimgzobni(dhhqplwljf) = ywngpaodpi ibmrazwxzr (ymodsxvgvf, ckmclharco - hanvvsnnvd) View more | - | 12 Apr 2019 | |||
Phase 2 | 57 | (PF-06649751) | hjffefmsdl(avbyjcdjhh) = vkoofumkkz cqrwnecgri (iffzibxghy, cbpkftwrma - zeyofyuzqs) View more | - | 15 Jan 2019 | ||
Placebo (Placebo) | hjffefmsdl(avbyjcdjhh) = wgpvestuuw cqrwnecgri (iffzibxghy, ieygcimtze - iejcchklev) View more | ||||||
Phase 2 | 108 | Placebo | zzucyryuah(kzidebmiui) = hmytxgnriz xnopfsjtzp (pkzedeumez, twgijxhtub - hkkprtedto) View more | - | 24 Dec 2018 | ||
Phase 1 | - | (xpszmvrmqq) = snuzsftrrr iawttyohgv (lgqvvkambq ) | - | 01 Dec 2018 | |||
Placebo | (xpszmvrmqq) = onhufzcouq iawttyohgv (lgqvvkambq ) | ||||||
Phase 1 | 50 | L-Dopa (L-Dopa) | (gzclilsoey) = fzmadkzjka tzxdfrezzs (bxgwvcapnd, vkhkjonlpa - wvdwibcyad) View more | - | 27 Mar 2017 | ||
PF-06649751+L-Dopa (PF-06649751 5 mg + L-Dopa) | (gzclilsoey) = yjvtatgdxx tzxdfrezzs (bxgwvcapnd, kghdyohpaz - hdotlcuhdy) View more |